Triple Therapy Reduces Hepatitis C Drug Resistance
A review in the February 2010 issue of Gastroenterology sites viral resistance against new medications as incentive for using triple therapy to treat Hepatitis C.
Three HCV Drug Candidates Proceed to Phase II
Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing.
Should Those with HCV Be Concerned About Bathing?
Find out how some with Hepatitis C unintentionally expose their skin to bath water contaminants that can place an additional burden on their liver.
More Hep C articles ... |